Co-administration of kla-TAT peptide and iRGD to enhance the permeability on A549 3D multiple sphere cells and accumulation on xenograft mice
© 2018 John Wiley & Sons A/S..
To enhance the anticancer activity, tumor penetration ability of the hybrid anticancer peptide, in this study, a TAT (RKKRRQRRR) peptide modified kla peptide (KLAKLAKKLAKLAK, with all D-amino acids), named kla-TAT, was co-administrated with the homing/penetrating peptide iRGD which could enhance the permeability of chemical drug in solid tumor and tumor vessel by co-administration. In this study, the nonsmall cell lung cancer A549 cell line with the iRGD targeting receptor neuropilin-1 high expression was selected to establish the 2D monolayer cell, 3D multiple cell spheroids, and xenograft mice model. The co-administration of iRGD strengthened the permeability of kla-TAT peptide against A549 2D and 3D sphere model with the penetration improvement property of iRGD; more importantly, co-administration with iRGD dramatically enhanced the accumulation of kla-TAT peptide in tumor tissue on the xenograft mice model with the homing property of iRGD. The co-administration of iRGD strategy confers targeting ability to the hybrid peptide kla-TAT. We believe the chemical conjugation plus co-administration approach may provide a promising way for cancer treatment in clinical practices.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:92 |
|---|---|
| Enthalten in: |
Chemical biology & drug design - 92(2018), 2 vom: 02. Aug., Seite 1567-1575 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hu, Cuihua [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 08.07.2019 Date Revised 08.01.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/cbdd.13323 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM28369372X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM28369372X | ||
| 003 | DE-627 | ||
| 005 | 20231225041506.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/cbdd.13323 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0945.xml |
| 035 | |a (DE-627)NLM28369372X | ||
| 035 | |a (NLM)29722179 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hu, Cuihua |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Co-administration of kla-TAT peptide and iRGD to enhance the permeability on A549 3D multiple sphere cells and accumulation on xenograft mice |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.07.2019 | ||
| 500 | |a Date Revised 08.01.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2018 John Wiley & Sons A/S. | ||
| 520 | |a To enhance the anticancer activity, tumor penetration ability of the hybrid anticancer peptide, in this study, a TAT (RKKRRQRRR) peptide modified kla peptide (KLAKLAKKLAKLAK, with all D-amino acids), named kla-TAT, was co-administrated with the homing/penetrating peptide iRGD which could enhance the permeability of chemical drug in solid tumor and tumor vessel by co-administration. In this study, the nonsmall cell lung cancer A549 cell line with the iRGD targeting receptor neuropilin-1 high expression was selected to establish the 2D monolayer cell, 3D multiple cell spheroids, and xenograft mice model. The co-administration of iRGD strengthened the permeability of kla-TAT peptide against A549 2D and 3D sphere model with the penetration improvement property of iRGD; more importantly, co-administration with iRGD dramatically enhanced the accumulation of kla-TAT peptide in tumor tissue on the xenograft mice model with the homing property of iRGD. The co-administration of iRGD strategy confers targeting ability to the hybrid peptide kla-TAT. We believe the chemical conjugation plus co-administration approach may provide a promising way for cancer treatment in clinical practices | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a accumulation | |
| 650 | 4 | |a co-administration | |
| 650 | 4 | |a iRGD | |
| 650 | 4 | |a kla-TAT | |
| 650 | 4 | |a permeability | |
| 650 | 7 | |a Intercellular Signaling Peptides and Proteins |2 NLM | |
| 650 | 7 | |a KLA peptide |2 NLM | |
| 650 | 7 | |a Oligopeptides |2 NLM | |
| 650 | 7 | |a Peptide Fragments |2 NLM | |
| 650 | 7 | |a Peptides |2 NLM | |
| 650 | 7 | |a tat Gene Products, Human Immunodeficiency Virus |2 NLM | |
| 650 | 7 | |a tat peptide (49-57), Human immunodeficiency virus 1 |2 NLM | |
| 650 | 7 | |a Neuropilin-1 |2 NLM | |
| 650 | 7 | |a 144713-63-3 |2 NLM | |
| 650 | 7 | |a arginyl-glycyl-aspartic acid |2 NLM | |
| 650 | 7 | |a 78VO7F77PN |2 NLM | |
| 700 | 1 | |a Chen, Xiaolong |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Yibing |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Yuxin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Chemical biology & drug design |d 2006 |g 92(2018), 2 vom: 02. Aug., Seite 1567-1575 |w (DE-627)NLM160848377 |x 1747-0285 |7 nnns |
| 773 | 1 | 8 | |g volume:92 |g year:2018 |g number:2 |g day:02 |g month:08 |g pages:1567-1575 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/cbdd.13323 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 92 |j 2018 |e 2 |b 02 |c 08 |h 1567-1575 | ||